Skip to main content
SpringerLink
Log in

Clinical Relevance of Drug Interactions with Lithium

  • Review Article
  • Pharmacokinetic Drug Interactions
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Although lithium continues to be regarded as the treatment of choice for bipolar disorders, the clinical use of this mood stabiliser is associated with an extremely narrow therapeutic range. Relatively minor increases in serum concentrations may induce serious adverse sequelae, and concentrations within the therapeutic range may result in toxic reactions. The safety of combining lithium with other medications, therefore, is a major concern, and extensive clinical experience has served to identify several significant drug interactions.

Lithium removal from the body is achieved almost exclusively via renal means. As a result, any medication that alters glomerular filtration rates or affects electrolyte exchange in the nephron may influence the pharmacokinetic disposition of lithium. Concomitant use of diuretics has long been associated with the development of lithium toxicity, but the risk of significant interactions varies with the site of pharmacological action of the diuretic in the renal tubule. Thiazide diuretics have demonstrated the greatest potential to increase lithium concentrations, with a 25 to 40% increase in concentrations often evident after initiation of therapy. Osmotic diuretics and methyl xanthines appear to have the opposite effect on lithium clearance and have been advocated historically as antidotes for lithium toxicity. Loop diuretics and potassium-sparing agents have minor variable effects.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have also been associated with lithium toxicity, although the relative interactive potential of specific NSAIDs is difficult to determine. Small prospective studies have demonstrated large interindividual differences in lithium clearance values associated with different NSAIDs. A growing body of evidence also suggests that ACE inhibitors may impair lithium elimination, but further investigations are needed to identify patients at risk.

Anecdotal reports have linked numerous medications with the development of neurotoxicity without an apparent effect on the pharmacokinetic disposition of lithium. Antipsychotics, anticonvulsants and calcium antagonists have all been implicated in a sufficient number of case reports to warrant concern. As these medications have all been commonly coadministered with lithium, the relative risk of serious interactions appears to be quite low, but caution is advised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jefferson JW. Lithium: the present and future. J Clin Psychiatry 1995; 56: 41–8

    Google Scholar 

  2. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349–52

    PubMed  CAS  Google Scholar 

  3. Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. JAMA 1949; 139: 685–8

    CAS  Google Scholar 

  4. Schou M, Baastrup PC. Lithium treatment of manic-depressive disorder: dosage and control. JAMA 1967; 201: 696–8

    PubMed  CAS  Google Scholar 

  5. Singer I. Lithium in mania. Clin Pharmacol Ther 1970; 11: 168–87

    Google Scholar 

  6. Meltzer HL. Mode of action of lithium in affective disorders: an influence on intracellular calcium functions. Pharmacol Toxicol 1990; 66 Suppl. 3: 84–99

    PubMed  CAS  Google Scholar 

  7. Holstein-Rathlou N-H. Lithium transport across biological membranes. Kidney Int 1990; 28 Suppl.: S4–9

    CAS  Google Scholar 

  8. Price LH, Charney DS, Delgado PL, et al. Lithium and serotonin function: implication for the serotonin hypothesis of depression. Psychopharmacology 1990: 100: 3–12

    PubMed  CAS  Google Scholar 

  9. Odagaki Y, Koyama Y, Yamashita I. Lithium and serotonergic neural transmission: a review of pharmacological and biochemical aspects in animal studies. Lithium 1992; 3: 95–107

    CAS  Google Scholar 

  10. Risby ED, Hsiao JK, Mahji HK, et al. The mechanism of lithium action. II. Effects on adenyl cyclase activity and beta adrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991; 48: 513–24

    PubMed  CAS  Google Scholar 

  11. Dilsaver SC. Lithium’s effects on muscarinic receptor binding parameters: a relationship to therapeutic efficacy? Biol Psychiatry 1984; 19: 1551–65

    PubMed  CAS  Google Scholar 

  12. Baraban J. Toward a crystal-clear view of lithium’s site of action. Proc Natl Acad Sci USA 1994; 91: 5738–9

    PubMed  CAS  Google Scholar 

  13. Coppen A, Abou-Saleh M, Millen P, et al. Decreasing lithium dosage reduces morbidity and side effects during prophylaxis. J Affect Disord 1983; 5: 353–62

    PubMed  CAS  Google Scholar 

  14. Gelenberg AJ, Wojcik JD, Falk WE, et al. Effects of lithium on the kidney. Acta Psychiatr Scand 1987; 75: 29–34

    PubMed  CAS  Google Scholar 

  15. Hestbeck J, Hansen HE, Amdisen A, et al. Chronic renal lesions following long term treatment with lithium. Kidney Int 1977; 12: 305–13

    Google Scholar 

  16. Perry PJ. Lithium nephrotoxicity. Drug Intell Clin Pharm 1982; 16: 740–4

    PubMed  CAS  Google Scholar 

  17. Kincaid-Smith P, Burrows GD, Davies BM, et al. Renal biopsy findings in lithium and pre-lithium patients. Lancet 1979; 2: 700–1

    PubMed  CAS  Google Scholar 

  18. Lokkegaard H, Anderson NF, Henriksen E, et al. Renal function in 153 manic-depressive patients treated with lithium for more than five years. Acta Psychiatr Scand 1985; 71: 347–55

    PubMed  CAS  Google Scholar 

  19. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–93

    PubMed  CAS  Google Scholar 

  20. Hammond CM. Single daily dosage of lithium carbonate. Ann Pharmacother 1994; 28: 472–3

    PubMed  CAS  Google Scholar 

  21. Carson SW. Lithium. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1990: 34-1–34-26

    Google Scholar 

  22. Jermain DM, Crismon ML, Mertin ES. Population pharmacokinetics of lithium. Clin Pharm 1991; 10: 376–81

    PubMed  CAS  Google Scholar 

  23. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994; 331: 591–8

    PubMed  CAS  Google Scholar 

  24. Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989; 36: 2–12

    PubMed  CAS  Google Scholar 

  25. Hayslett JP, Kashgarian M. A micropuncture study of the renal handling of lithium. Pflugers Arch 1979; 380: 159–63

    PubMed  CAS  Google Scholar 

  26. Okusa MD, Crystal LJ. Clinical manifestations and management of lithium intoxication. Am J Med 1994; 97: 383–9

    PubMed  CAS  Google Scholar 

  27. Kamper AL, Strandgaard S, Holstein-Rathlou N-H, et al. The influence of body posture on lithium clearance. Scand J Clin Lab Invest 1988; 48: 509–12

    PubMed  CAS  Google Scholar 

  28. Kirchner KA. Lithium as a marker for proximal tubule delivery during low salt intake and diuretic infusion. Am J Physiol 1987; 253: F188–96

    PubMed  CAS  Google Scholar 

  29. Macfie AC. Lithium poisoning precipitated by diuretics [letter]. BMJ 1975; 1: 516

    PubMed  CAS  Google Scholar 

  30. Solomon JG. Lithium toxicity precipitated by a diuretic. Psychosomatics 1980; 21: 425–9

    PubMed  CAS  Google Scholar 

  31. Kerry RJ, Ludlow JM, Owen G. Lesson of the week — diuretics are dangerous with lithium. BMJ 1980; 281: 371

    PubMed  CAS  Google Scholar 

  32. Levy ST, Forrest JN, Heninger GR. Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. Am J Psychiatry 1973; 130: 1014–8

    PubMed  CAS  Google Scholar 

  33. Poust RI, Mallinger AG, Mallinger J, et al. Effect of chlorothiazide on the pharmacokinetics of lithium in plasma and erythrocytes. Psychopharmacol Commun 1976; 2: 273–84

    PubMed  CAS  Google Scholar 

  34. Jefferson JW, Kalin NH. Serum lithium levels and long-term diuretic use. JAMA 1979; 241: 1134–6

    PubMed  CAS  Google Scholar 

  35. Crabtree BL, Mack JE, Johnson CD, et al. Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition. Am J Psychiatry 1991; 148: 1060–3

    PubMed  CAS  Google Scholar 

  36. Jakobsson B, Berg U. Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus. Acta Paediatr 1994; 83: 522–5

    PubMed  CAS  Google Scholar 

  37. Himmelhoch JM, Poust RI, Mallinger AG, et al. Adjustment of lithium dose during lithium-chlorothiazide therapy. Clin Pharmacol Ther 1977; 22: 225–7

    PubMed  CAS  Google Scholar 

  38. Hertig HI, Dyson WL. Lithium toxicity enhanced by diuretics. N Engl J Med 1974; 290: 748–9

    Google Scholar 

  39. Oh TE. Frusemide and lithium toxicity. Anaesth Intensive Care 1977; 5: 60–2

    PubMed  CAS  Google Scholar 

  40. Huang LG. Lithium intoxication and coadministration of a loop-diuretic [letter]. J Clin Psychopharmacol 1990; 10: 228

    PubMed  CAS  Google Scholar 

  41. Steele TH, Dudgeon KL, Larmore CK. Pharmacological characterization of lithium reabsorption in the rat. J Pharmacol Exp Ther 1976; 196: 188–93

    PubMed  CAS  Google Scholar 

  42. Shirley DG, Walter SJ, Sampson B. A micropuncture study of renal lithium reabsorption: effects of amiloride and furosemide. Am J Physiol 1992; 263: F1128–33

    PubMed  CAS  Google Scholar 

  43. McNabb WR, Noormohamed FH, Brooks BA, et al. Renal action of piretanide and three other ‘loop’ diuretics. Clin Pharmacol Ther 1984; 35: 328–37

    PubMed  CAS  Google Scholar 

  44. Atherton JC, Doyle A, Gee A, et al. Lithium clearance: modification by the loop of Henle in man. J Physiol 1991; 437: 377–91

    PubMed  CAS  Google Scholar 

  45. Thomsen K, Schou M. Renal excretion in man. Am J Physiol 1968; 215: 823–7

    PubMed  CAS  Google Scholar 

  46. Saffer D, Coppen A. Frusemide: a safe diuretic during lithium therapy? J Affect Disord 1983; 5: 289–92

    PubMed  CAS  Google Scholar 

  47. Obek A. Mannitol infusions and lithium excretion [letter]. BMJ 1972; 4: 550

    PubMed  CAS  Google Scholar 

  48. Shneerson JM. Acute lithium intoxication. Br J Clin Pract 1978; 32: 232, 237

    PubMed  CAS  Google Scholar 

  49. Baer L, Platman SR, Kassir S, et al. Mechanisms of lithium handling and their relationship to mineralocorticoids: a disassociation between sodium and lithiumions. J Psychiatr Res 1971; 8: 91–105

    PubMed  CAS  Google Scholar 

  50. Batlle DC, von Riotte AB, Gaviria M, et al. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312: 408–14

    PubMed  CAS  Google Scholar 

  51. Kosten TR, Forrest JN. Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 1986; 143: 1563–8

    PubMed  CAS  Google Scholar 

  52. Thomsen K, Leysac PP. Acute effects of various diuretics on lithium clearance. Renal Physiol 1986; 9: 1–8

    PubMed  CAS  Google Scholar 

  53. Perry PJ, Calloway RA, Cook BL, et al. Theophylline precipitated alterations of lithium clearance. Acta Psychiatr Scand 1984; 69: 528–37

    PubMed  CAS  Google Scholar 

  54. Holstad SG, Perry PJ, Kathol RG, et al. The effects of intravenous theophylline infusion on lithium clearance in normal subjects. Psychiatr Res 1988; 25: 203–11

    CAS  Google Scholar 

  55. Furlong FW. Possible psychiatric significance of excesssive coffee consumption. Can Psychiatr Assoc J 1975; 20: 577–83

    PubMed  CAS  Google Scholar 

  56. Bikin D, Conrad KA, Mayersohn M. Lack of influence of caffeine and aspirin on lithium elimination [abstract]. Clin Res 1982; 30: 249A

    Google Scholar 

  57. Mester R, Toren P, Mizrachi I, et al. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry 1995; 37: 348–50

    PubMed  CAS  Google Scholar 

  58. Douste-Blazy P, Rostin M, Livarek B, et al. Angiotensin-con-verting enzyme inhibitors and lithium treatment [letter]. Lancet 1986; 1: 1448

    PubMed  CAS  Google Scholar 

  59. Mahieu M, Houvenagel E, Leduc JJ, et al. Lithium inhibitors of converting-enzyme, an association to be avoided [letter]. Presse Med 1988; 17: 281

    PubMed  CAS  Google Scholar 

  60. Pulik M, Lida H. Interaction between lithium and angiotensin-converting enzyme inhibitors [letter]. Presse Med 1988; 17: 755

    PubMed  CAS  Google Scholar 

  61. Conrad AJ. Ace inhibitors and lithium toxicity. Mass Gen Hosp Newslett 1988; 2: 43

    Google Scholar 

  62. Navis GJ, de Jong PE, de Zeeuw D. Volume homeostasis, angiotensin-converting enzyme inhibition, and lithium therapy [letter]. Am J Med 1989; 86: 621

    PubMed  CAS  Google Scholar 

  63. Drouet A, Bouvet O. Lithium et inhibitors de l’enzyme de conversion. Encephale 1990; 16: 51–2

    PubMed  CAS  Google Scholar 

  64. Baldwin CM, Safferman AZ. A case of lisinopril-induced lithium toxicity. DICP 1990; 24: 946–7

    PubMed  CAS  Google Scholar 

  65. Griffin JH, Hahn SM. Lisinopril-induced lithium toxicity [letter]. DICP 1991; 25: 101

    PubMed  CAS  Google Scholar 

  66. Correa FJ, Eiser AR. Angiotensin-converting enzyme inhibitors and lithium toxicity. Am J Med 1992; 93: 108–9

    PubMed  CAS  Google Scholar 

  67. Das Gupta K, Jefferson JW, Kobak KA, et al. The effect of enalopril on serum lithium levels in healthy men. J Clin Psychiatry 1992; 53: 398–400

    Google Scholar 

  68. Finley PR, O’Brien JG, Coleman RW. Lithium and angiotensin converting enzyme inhibitor drug interaction. J Clin Psychopharmacol 1995. In press

  69. Brunner HR, Waeber B, Nussberger J. Renal effects of converting enzyme inhibition. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: 6–14

    Google Scholar 

  70. Ganong WF. The brain renin-angiotensin system. Ann Rev Physiol 1984; 46: 17–31

    CAS  Google Scholar 

  71. Mason NA. Angiotensin-converting enzyme inhibitors and renal function. DICP 1990; 24: 496–505

    PubMed  CAS  Google Scholar 

  72. Valdiserri EV. A possible interaction between lithium and diltiazem: a case report. J Clin Psychiatry 1985; 46: 540–1

    PubMed  CAS  Google Scholar 

  73. Dubovsky SI, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry 1987; 48: 371–2

    PubMed  CAS  Google Scholar 

  74. Price WA, Shalley JE. Lithium-verapamil toxicity in the elderly. J Am Geriatr Soc 1987; 35: 177–8

    PubMed  CAS  Google Scholar 

  75. Binder EF, Cayabyab L, Ritchie DJ, et al. Psychosis and a possible diltiazem-lithium interaction. Arch Intern Med 1991; 151: 373–4

    PubMed  CAS  Google Scholar 

  76. Wright BA, Jarrett DB. Lithium and calcium channel blockers: possible neurotoxicity. Biol Psychiatry 1991; 30: 635–6

    PubMed  CAS  Google Scholar 

  77. Jacobsen FM, Sack DA, James SP. Delirium induced by verapamil. Am J Psychiatry 1987; 144: 248

    PubMed  CAS  Google Scholar 

  78. Bushe CJ. Organic psychosis caused by diltiazem. J R Soc Med 1988; 81: 296–7

    Google Scholar 

  79. Bruun NE, Ibsen H, Skott P. Lithium clearance and renal tubular sodium handling during acute and long-term nifedipine treatment in essential hypertension. Clin Sci 1988; 75: 609–13

    PubMed  CAS  Google Scholar 

  80. Leftwich R, Walker R, Smigel M, et al. Indomethacin is antidiuretic in lithium-induced diabetes insipidus [abstract]. Clin Res 1977; 25: 272A

    Google Scholar 

  81. Leftwich RB, Walker LA, Ragheb M, et al. Inhibition of prostaglandin synthesis increases plasma lithium levels [abstract]. Clin Res 1978; 26: 219A

    Google Scholar 

  82. Frolich JC, Leftwich R, Ragheb M, et al. Indomethacin increases plasma lithium. BMJ 1979; 1: 1115–6

    PubMed  CAS  Google Scholar 

  83. Reimann IW, Diener U, Frolich JC. Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry 1983; 40: 283–6

    PubMed  CAS  Google Scholar 

  84. Ragheb M. Ibuprofen can increase serum lithium level in lithium-treated patients. J Clin Psychiatry 1987; 48: 161–3

    PubMed  CAS  Google Scholar 

  85. Reimann IG, Frolich JC. Effect of diclofenac on lithium kinetics. Clin Pharmacol Ther 1981; 30: 348–52

    PubMed  CAS  Google Scholar 

  86. Ragheb M, Powell AL. Lithium interaction with sulindac and naproxen. J Clin Psychopharmacol 1986; 6: 150–4

    PubMed  CAS  Google Scholar 

  87. Ragheb MA. Aspirin does not significantly effect patients’ serum lithium levels [letter]. J Clin Psychiatry 1987; 48: 425

    PubMed  CAS  Google Scholar 

  88. Ragheb MA, Powell RA. Failure of sulindac to increase serum lithium levels. J Clin Psychiatry 1986; 47: 33–4

    PubMed  CAS  Google Scholar 

  89. Ayd FJ. Lithium-mefenamic acid interaction. Int Drug Ther Newsl 1982; 17: 16

    Google Scholar 

  90. Shelley RK. Lithium toxicity and mefenamic acid: a possible interaction and the role of prostaglandin inhibition. Br J Psychiatry 1987; 151: 847–8

    PubMed  CAS  Google Scholar 

  91. Kerry RJ, Owen G, Michaelson S. Possible toxic interaction between lithium and piroxicam. Lancet 1983; 1: 418–9

    PubMed  CAS  Google Scholar 

  92. Nadarajah J, Stein GS. Piroxicam induced lithium toxicity [letter]. Ann Rheum Dis 1985; 44: 502

    PubMed  CAS  Google Scholar 

  93. Iyer V. Ketorolac induced lithium toxicity. Headache 1994; 34: 442–4

    PubMed  CAS  Google Scholar 

  94. Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interaction. J Clin Psychopharmacol 1990; 10: 350–4

    PubMed  CAS  Google Scholar 

  95. Prakash R, Kelwala S, Ban TA. Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 1982; 23: 567–71

    PubMed  CAS  Google Scholar 

  96. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. JAMA 1974; 230: 1283–7

    PubMed  CAS  Google Scholar 

  97. Marhold J, Zimanova J, Lachman M, et al. To the incompatibility of haloperidol with lithium salts. Acta Nerv Super 1974; 16: 199–200

    CAS  Google Scholar 

  98. Thornton WE, Pray BJ. Lithium intoxication: a report of 2 cases. Can Psychiatr Assoc J 1975; 20: 281–2

    PubMed  CAS  Google Scholar 

  99. Spring G, Frankel M. New data on lithium and haloperidol incompatibility. Am J Psychiatry 1981; 138: 818–21

    PubMed  CAS  Google Scholar 

  100. Spring G. Neurotoxicity with combined use of lithium and thi-oridazine. J Clin Psychiatry 1979; 40: 135–8

    PubMed  CAS  Google Scholar 

  101. Alevizos B. Toxic reactions to lithium and neuroleptics [letter]. BrJ Psychiatry 1979; 135: 482

    CAS  Google Scholar 

  102. Spring G, Abrams R, Raylor MA. EEG observations in confirming neurotoxicity. Am J Psychiatry 1979; 136: 1099–100

    PubMed  CAS  Google Scholar 

  103. Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493–5

    PubMed  Google Scholar 

  104. Blake LM, Marks RC, Luchins DJ. Reversible neurological symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12: 297–9

    PubMed  CAS  Google Scholar 

  105. Swanson Jr CL, Price WA, McEvoy JP, et al. Effects of concomitant risperidone and lithium treatment [letter]. Am J Psychiatry 1995; 152(7): 1096

    PubMed  Google Scholar 

  106. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57–67

    PubMed  CAS  Google Scholar 

  107. Ayd FJ. Lithium-haloperidol formulation: is it safe or hazardous? Int Drug Ther Newsl 1975; 10: 29–36

    Google Scholar 

  108. Baastrup PC, Hollnagel P, Sorensen P, et al. Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA 1976; 236: 2645–6

    PubMed  CAS  Google Scholar 

  109. Goldney RD, Spence ND. Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986; 143: 882–4

    PubMed  CAS  Google Scholar 

  110. Addonzio G, Roth SD, Stokes PE, et al. Increased extra-pyramidal symptoms with the addition of lithium to neuroleptics. J Nerv Ment Dis 1988; 176: 682–5

    Google Scholar 

  111. Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7: 89–91

    PubMed  CAS  Google Scholar 

  112. Kessel JB, Verghese C, Simpson G. Neurotoxicity related to lithium and neuroleptic combinations? A retrospective review. J Psychiatry Neurosci 1992; 17: 28–30

    PubMed  CAS  Google Scholar 

  113. Pandey GN, Goel I, Davis JM. Effect of neuroleptic drugs on lithium uptake by human erythrocyte. Clin Pharmacol Ther 1979; 26: 96–102

    PubMed  CAS  Google Scholar 

  114. von Knorring L, Smigan L, Perris C, et al. Lithium and neuroleptic drugs in combination — effect on lithium RBC/plasma ratio. Int Pharmacopsychiatry 1982; 17: 287–92

    Google Scholar 

  115. Schou M. Lithium and treatment-resistant depression: a review. Lithium 1990; 1: 3–8

    Google Scholar 

  116. Solomon JG. Seizures during lithium-amitriptyline therapy. Postgrad Med J 1979; 66: 145–6

    CAS  Google Scholar 

  117. Rosenberg PB, Pearlman CA. NMS-like syndrome with a lithium/doxepin combination. J Clin Psychopharmacol 1991; 11: 75–6

    PubMed  CAS  Google Scholar 

  118. Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant therapy in elderly patients. J Clin Psychiatry 1990; 51: 344–5

    PubMed  CAS  Google Scholar 

  119. Shah AK, McCloskey O. Case report: acute confusional state secondary to a combination of fluoxetine and lithium. Int J Geriatr Psychiatry 1992; 7: 687–8

    Google Scholar 

  120. Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993; 26: 263–4

    PubMed  CAS  Google Scholar 

  121. Muly EC, McDonald W, Steffans D, et al. Serotonin syndrome induced by a combination of fluoxetine and lithium [letter]. Am J Psychiatry 1993; 150: 1565

    PubMed  CAS  Google Scholar 

  122. Salama AA, Shafey M. A case of serious lithium toxicity induced by combined fluoxetine and lithium carbonate [letter]. Am J Psychiatry 1989; 146: 278

    PubMed  CAS  Google Scholar 

  123. Wilner KD, Lazar JD, Von Deutsch DA, et al. The effects of sertraline on steady state lithium levels and renal clearance in man [abstract]. Biol Psychiatry 1991; 29: 354S

    Google Scholar 

  124. Hendrickx B, Flores M. A controlled pilot study of the combination of fluvoxamine and lithium. Curr Ther Res 1991; 49: 106–10

    Google Scholar 

  125. Data on file. SmithKline Beecham Pharmaceuticals, Philadelphia, 1993

  126. Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine and lithium. Ther Drug Monit 1993; 15: 18–24

    PubMed  CAS  Google Scholar 

  127. Omura F, Kishimoto A, Tsutsui T, et al. Combined therapy of lithium and carbamazepine in bipolar affective disorders. Folia Psychiatr Neurol Jpn 1984; 38: 401–2

    Google Scholar 

  128. Post RM, Kramlinger K, Uhde TW. Carbamazepine-lithium combination: clinical efficacy and side effects. Int Drug Ther Newsl 1987; 22: 5–8

    Google Scholar 

  129. Chaudhry RP, Waters BGH. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983; 44: 30–1

    PubMed  CAS  Google Scholar 

  130. Shukla S, Godwin CD, Long EB, et al. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984; 141: 1604–6

    PubMed  CAS  Google Scholar 

  131. Price WA, Zimmer B. Lithium-carbamazepine neurotoxicity in the elderly. J Am Geriatr Soc 1985; 33: 876–7

    PubMed  CAS  Google Scholar 

  132. Ghose K. Effect of carbamazepine in polyuria associated with lithium therapy. Pharmacopsychiatry 1978; 11: 241–5

    CAS  Google Scholar 

  133. Rybakowski JK, Lehman W, Kanarkowski R, et al. Possible pharmacokinetic interaction of lithium and carbamazepine. Lithium 1991; 2: 183–4

    CAS  Google Scholar 

  134. Yang YY, Dong HC. Influence of carbamazepine on lithium ratio in healthy volunteers: an in vitro method. Clin Neuropharmacol 1993; 16: 216–9

    PubMed  CAS  Google Scholar 

  135. McGinness J, Kishimoto A, Hollister LE. Avoiding toxicity with lithium-carbamazepine combination. Psychopharmacol Bull 1990; 26: 181–4

    PubMed  CAS  Google Scholar 

  136. Shopsin D, Johnson G, Gershon S. Neurotoxicity with lithium: differential drug responsiveness. Int Pharmacopsychiatry 1970; 5: 170–82

    Google Scholar 

  137. Speirs J, Hirsch SR. Severe lithium toxicity with ‘normal’ serum concentrations. BMJ 1978; 1: 815–6

    PubMed  CAS  Google Scholar 

  138. MacCallum WAG. Interaction of lithium and phenytoin. BMJ 1980; 280: 610–1

    PubMed  CAS  Google Scholar 

  139. Salem RB, Director K, Muniz CE. Ataxia as the primary symptom of lithium toxicity. Drug Intell Clin Pharm 1980; 14: 622–3

    Google Scholar 

  140. Graham-Smith DG, Green AR. The role of brain 5-hydroxy-tryptamine in the hyperactivity produced by rats by lithium and monoamine oxidase inhibitors. Br J Pharmacol 1974; 52: 19–26

    Google Scholar 

  141. Green AR, Graham-Smith DG. The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology 1975; 14: 107–13

    PubMed  CAS  Google Scholar 

  142. Borden H, Clarke MT, Katz H. The use of pancuronium bromide in patients receiving lithium carbonate. Can Aneasth Soc J 1974; 21: 79–82

    CAS  Google Scholar 

  143. Hill GE, Wong KC, Hodges MR. Potentiation of succinylcholine neuromuscular blockade by lithium carbonate. Anesthesiology 1976; 44: 439–42

    PubMed  CAS  Google Scholar 

  144. Whittaker M, Spencer R. Plasma cholinesterase variants in patients receiving lithium therapy. Clin Chim Acta 1977; 75: 421–5

    PubMed  CAS  Google Scholar 

  145. Arthur RK. Lithium levels and ‘Soda Bic’ [letter]. Med J Aust 1975; 2: 918

    PubMed  CAS  Google Scholar 

  146. McSwiggan C. Interaction of lithium and bicarbonate. Med J Aust 1978; 1: 38–9

    PubMed  CAS  Google Scholar 

  147. Holstad HG, Perry PJ, Kathol RG, et al. The effects of i.v. theophylline infusion versus i.v. sodium bicarbonate infusion on lithium clearance in normal subjects [reprint]. Psychiatr Res 1988; 25: 203–11

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Palo Alto Veterans Affairs Health Care System, Menlo Park Division, Menlo Park, California, USA

    Patrick R. Finley & Cecilia A. Peabody

  2. University of California, San Francisco, California, USA

    Patrick R. Finley

  3. Stanford University, Stanford, California, USA

    M. Dhyanne Warner

Authors
  1. Patrick R. Finley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Dhyanne Warner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cecilia A. Peabody
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finley, P.R., Warner, M.D. & Peabody, C.A. Clinical Relevance of Drug Interactions with Lithium. Clin-Pharmacokinet 29, 172–191 (1995). https://doi.org/10.2165/00003088-199529030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199529030-00004

Keywords

Search

Navigation